The third-generation ALK inhibitor Lorviqua has settled in the Big Five Hospital. According to related industries, Lorviqua of Pfizer Korea passed the Drug Committee of Big 5 (DC), excluding Seoul St. Mary's Hospital such as Samsung Medical Center, Seoul National Cancer Center, and Chung-Ang University Hospital.

As the adequacy of insurance benefits was recognized by the Drug Benefit Evaluation Committee last month after passing the first HIRA Cancer Disease Review Committee in January, it is expected to be quickly linked to actual prescriptions if the registration of Lorviqua is confirmed. It remains to be seen whether Pfizer, the first developer of ALK anticancer drugs, will be able to increase its ma